Literature DB >> 27772640

Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.

Michael Copland1, Paul Komenda2, Eric D Weinhandl3, Peter A McCullough4, Jose A Morfin5.   

Abstract

Mineral and bone disorder is a common complication of end-stage renal disease. Notably, hyperphosphatemia likely promotes calcification of the myocardium, valves, and arteries. Hyperphosphatemia is associated with higher risk for cardiovascular mortality and morbidity along a gradient beginning at 5.0mg/dL. Among contemporary hemodialysis (HD) patients, mean serum phosphorus level is 5.2mg/dL, although 25% of patients have serum phosphorus levels of 5.5 to 6.9mg/dL; and 13%, >7.0mg/dL. Treatment of hyperphosphatemia is burdensome. Dialysis patients consume a mean of 19 pills per day, half of which are phosphate binders. Medicare Part D expenditures on binders for dialysis patients approached $700 million in 2013. Phosphorus removal with thrice-weekly HD (4 hours per session) is ∼3,000mg/wk. However, clearance is unlikely to counterbalance dietary intake, which varies around a mean of 7,000mg/wk. Dietary restriction and phosphate binders are important interventions, but each has limitations. Dietary control is complicated by limited access to healthy food choices and unclear labeling. Meanwhile, adherence to phosphate binders is poor, especially in younger patients and those with high pill burden. Multiple randomized clinical trials show that intensive HD reduces serum phosphorus levels. In the Frequent Hemodialysis Network (FHN) trial, short daily and nocturnal schedules reduced serum phosphorus levels by 0.6 and 1.6mg/dL, respectively, relative to 3 sessions per week. A similar effect of nocturnal HD was observed in an earlier trial. In the daily arm of the FHN trial, intensive HD significantly lowered estimated phosphate binder dose per day, whereas in the nocturnal arm, intensive HD led to binder discontinuation in 75% of patients. However, intensive HD appears to have no meaningful effects on serum calcium and parathyroid hormone concentrations. In conclusion, intensive HD, especially nocturnal HD, lowers serum phosphorus levels and decreases the need for phosphate binders.
Copyright © 2016 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chronic kidney disease; Frequent Hemodialysis Network; calcium; cinacalcet; daily dialysis; end stage renal disease (ESRD); home dialysis; intensive hemodialysis; mineral and bone disorder (MBD); nocturnal hemodialysis; parathyroid hormone; phosphate binder; phosphorus; review; secondary hyperparathyroidism; short daily hemodialysis; vascular calcification

Mesh:

Substances:

Year:  2016        PMID: 27772640     DOI: 10.1053/j.ajkd.2016.05.024

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  12 in total

1.  Comparative Effectiveness of Dialysis Modality on Laboratory Parameters of Mineral Metabolism.

Authors:  Melissa Soohoo; Yoshitsugu Obi; Matthew B Rivara; Scott V Adams; Wei Ling Lau; Connie M Rhee; Csaba P Kovesdy; Kamyar Kalantar-Zadeh; Onyebuchi A Arah; Rajnish Mehrotra; Elani Streja
Journal:  Am J Nephrol       Date:  2022-02-28       Impact factor: 4.605

2.  Hemodialysis With the Quanta SC+: Efficacy and Safety of a Self-care Hemodialysis Machine.

Authors:  Paul V J Komenda; Gerard Harper; Lucy M Wilson; Sandip Mitra; Cormac Breen; John E Milad
Journal:  Kidney Med       Date:  2020-10-21

Review 3.  The Diet and Haemodialysis Dyad: Three Eras, Four Open Questions and Four Paradoxes. A Narrative Review, Towards a Personalized, Patient-Centered Approach.

Authors:  Giorgina Barbara Piccoli; Maria Rita Moio; Antioco Fois; Andreea Sofronie; Lurlinys Gendrot; Gianfranca Cabiddu; Claudia D'Alessandro; Adamasco Cupisti
Journal:  Nutrients       Date:  2017-04-10       Impact factor: 5.717

4.  Home hemodialysis treatment and outcomes: retrospective analysis of the Knowledge to Improve Home Dialysis Network in Europe (KIHDNEy) cohort.

Authors:  Shashidhar Cherukuri; Maria Bajo; Giacomo Colussi; Roberto Corciulo; Hafedh Fessi; Maxence Ficheux; Maria Slon; Eric Weinhandl; Natalie Borman
Journal:  BMC Nephrol       Date:  2018-10-11       Impact factor: 2.388

5.  Application of dynamic optimisation for planning a haemodialysis process.

Authors:  Wojciech Stecz; Radoslaw Pytlak; Aleksandra Rymarz; Stanislaw Niemczyk
Journal:  BMC Nephrol       Date:  2019-07-02       Impact factor: 2.388

6.  State-of-the-Art Management of Hyperphosphatemia in Patients With CKD: An NKF-KDOQI Controversies Perspective.

Authors:  Julia J Scialla; Jessica Kendrick; Jaime Uribarri; Csaba P Kovesdy; Orlando M Gutiérrez; Elizabeth Yakes Jimenez; Holly J Kramer
Journal:  Am J Kidney Dis       Date:  2020-08-06       Impact factor: 8.860

7.  Potentiometric Phosphate Ion Sensor Based on Electrochemical Modified Tungsten Electrode.

Authors:  Kebin Xu; Ying Li; Min Li
Journal:  ACS Omega       Date:  2021-05-20

8.  Investigation of nicotinamide as more than an anti-phosphorus drug in chronic hemodialysis patients: a single-center, double-blind, randomized, placebo-controlled trial.

Authors:  Xiang-Yang Liu; Jing-Rui Yao; Rong Xu; Lin-Xin Xu; Yue-Feng Zhang; Shan Lu; Zhi-Heng Xing; Li-Ping Fan; Zhong-Hua Qin; Bei Sun
Journal:  Ann Transl Med       Date:  2020-04

Review 9.  Integrated care: enhancing transition from renal replacement therapy options to home haemodialysis.

Authors:  Maria Fernanda Slon Roblero; Natalie Borman; Maria Auxiliadora Bajo Rubio
Journal:  Clin Kidney J       Date:  2019-11-18

Review 10.  Intradialytic Nutrition and Hemodialysis Prescriptions: A Personalized Stepwise Approach.

Authors:  Giorgina Barbara Piccoli; Francoise Lippi; Antioco Fois; Lurlynis Gendrot; Louise Nielsen; Jerome Vigreux; Antoine Chatrenet; Claudia D'Alessandro; Gianfranca Cabiddu; Adamasco Cupisti
Journal:  Nutrients       Date:  2020-03-16       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.